Which has preferable valuation and earnings, IMVT or BIIB?

Biogen has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.82 N/A Biogen $10.03B 3.09 $1.29B $5.65 37.09

Is IMVT or BIIB more profitable?

Biogen has a net margin of 8.32% compared to Immunovant's net margin of 0.00%. Biogen's return on equity of 11.18% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Biogen 8.32% 11.18% 6.88%

Does the media favor IMVT or BIIB?

In the previous week, Biogen had 1 more articles in the media than Immunovant. MarketBeat recorded 9 mentions for Biogen and 8 mentions for Immunovant. Immunovant's average media sentiment score of 1.04 beat Biogen's score of 0.92 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IMVT or ALNY?

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Immunovant. MarketBeat recorded 13 mentions for Alnylam Pharmaceuticals and 8 mentions for Immunovant. Immunovant's average media sentiment score of 1.04 beat Alnylam Pharmaceuticals' score of 0.26 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IMVT or ROIV?

In the previous week, Immunovant had 1 more articles in the media than Roivant Sciences. MarketBeat recorded 8 mentions for Immunovant and 7 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.25 beat Immunovant's score of 1.04 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, INCY or IMVT?

Incyte has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 4.71 $1.29B $7.85 15.22 Immunovant N/A N/A -$505.61M -$2.82 N/A

Is INCY or IMVT more profitable?

Incyte has a net margin of 27.71% compared to Immunovant's net margin of 0.00%. Incyte's return on equity of 29.93% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% Immunovant N/A -69.59% -62.49%

Does the media refer more to INCY or IMVT?

In the previous week, Immunovant had 3 more articles in the media than Incyte. MarketBeat recorded 8 mentions for Immunovant and 5 mentions for Incyte. Incyte's average media sentiment score of 1.69 beat Immunovant's score of 1.04 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immunovant 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BNTX or IMVT more profitable?

Immunovant has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -63.54% -6.86% -6.00% Immunovant N/A -69.59% -62.49%

Does the media favor BNTX or IMVT?

In the previous week, BioNTech had 3 more articles in the media than Immunovant. MarketBeat recorded 11 mentions for BioNTech and 8 mentions for Immunovant. Immunovant's average media sentiment score of 1.04 beat BioNTech's score of 0.58 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immunovant (IMVT) Competitors

$41.31 -0.51 (-1.21%)

As of 12:21 PM Eastern

Compare

IMVT vs. BIIB, ALNY, ROIV, INCY, and BNTX

Should you buy Immunovant stock or one of its competitors? Immunovant's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Roivant Sciences (ROIV), Incyte (INCY), and BioNTech (BNTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immunovant compare to Biogen?

Immunovant (NASDAQ:IMVT) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 1.9% of Immunovant shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Biogen has a net margin of 8.32% compared to Immunovant's net margin of 0.00%. Biogen's return on equity of 11.18% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Biogen	8.32%	11.18%	6.88%

Biogen has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Biogen	$10.03B	3.09	$1.29B	$5.65	37.09

Immunovant presently has a consensus price target of $44.00, suggesting a potential upside of 7.21%. Biogen has a consensus price target of $227.07, suggesting a potential upside of 8.37%. Given Biogen's stronger consensus rating and higher probable upside, analysts plainly believe Biogen is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Immunovant has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market.

In the previous week, Biogen had 1 more articles in the media than Immunovant. MarketBeat recorded 9 mentions for Biogen and 8 mentions for Immunovant. Immunovant's average media sentiment score of 1.04 beat Biogen's score of 0.92 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biogen beats Immunovant on 13 of the 16 factors compared between the two stocks.

How does Immunovant compare to Alnylam Pharmaceuticals?

Immunovant (NASDAQ:IMVT) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Immunovant's net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Immunovant. MarketBeat recorded 13 mentions for Alnylam Pharmaceuticals and 8 mentions for Immunovant. Immunovant's average media sentiment score of 1.04 beat Alnylam Pharmaceuticals' score of 0.26 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunovant has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

Alnylam Pharmaceuticals has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Alnylam Pharmaceuticals	$4.80B	6.26	$313.75M	$5.38	41.77

47.1% of Immunovant shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 1.9% of Immunovant shares are held by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Immunovant currently has a consensus price target of $44.00, indicating a potential upside of 7.21%. Alnylam Pharmaceuticals has a consensus price target of $393.86, indicating a potential upside of 75.25%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92

Summary

Alnylam Pharmaceuticals beats Immunovant on 13 of the 16 factors compared between the two stocks.

How does Immunovant compare to Roivant Sciences?

Immunovant (NASDAQ:IMVT) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Roivant Sciences has higher revenue and earnings than Immunovant. Roivant Sciences is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Roivant Sciences	$8.26M	3,164.88	-$299.77M	-$0.53	N/A

Immunovant has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Immunovant has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Immunovant presently has a consensus price target of $44.00, indicating a potential upside of 7.21%. Roivant Sciences has a consensus price target of $35.14, indicating a potential downside of 3.33%. Given Immunovant's higher probable upside, analysts clearly believe Immunovant is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 1.9% of Immunovant shares are owned by company insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Immunovant had 1 more articles in the media than Roivant Sciences. MarketBeat recorded 8 mentions for Immunovant and 7 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.25 beat Immunovant's score of 1.04 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Roivant Sciences beats Immunovant on 12 of the 16 factors compared between the two stocks.

How does Immunovant compare to Incyte?

Incyte (NASDAQ:INCY) and Immunovant (NASDAQ:IMVT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

97.0% of Incyte shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 16.2% of Incyte shares are owned by insiders. Comparatively, 1.9% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Incyte has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

In the previous week, Immunovant had 3 more articles in the media than Incyte. MarketBeat recorded 8 mentions for Immunovant and 5 mentions for Incyte. Incyte's average media sentiment score of 1.69 beat Immunovant's score of 1.04 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Immunovant	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte presently has a consensus target price of $120.65, indicating a potential upside of 0.95%. Immunovant has a consensus target price of $44.00, indicating a potential upside of 7.21%. Given Immunovant's stronger consensus rating and higher possible upside, analysts plainly believe Immunovant is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Incyte has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.71	$1.29B	$7.85	15.22
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

Incyte has a net margin of 27.71% compared to Immunovant's net margin of 0.00%. Incyte's return on equity of 29.93% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Immunovant	N/A	-69.59%	-62.49%

Summary

Incyte beats Immunovant on 11 of the 15 factors compared between the two stocks.

How does Immunovant compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Immunovant (NASDAQ:IMVT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

Immunovant has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Immunovant	N/A	-69.59%	-62.49%

Immunovant has lower revenue, but higher earnings than BioNTech. Immunovant is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.16	-$1.29B	-$7.83	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

BioNTech presently has a consensus price target of $127.81, indicating a potential upside of 38.98%. Immunovant has a consensus price target of $44.00, indicating a potential upside of 7.21%. Given BioNTech's stronger consensus rating and higher probable upside, equities analysts plainly believe BioNTech is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 1.9% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, BioNTech had 3 more articles in the media than Immunovant. MarketBeat recorded 11 mentions for BioNTech and 8 mentions for Immunovant. Immunovant's average media sentiment score of 1.04 beat BioNTech's score of 0.58 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Summary

BioNTech beats Immunovant on 11 of the 16 factors compared between the two stocks.

Get Immunovant News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMVT vs. The Competition

Export

Metric	Immunovant	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.49B	$3.69B	$6.97B	$13.06B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-14.57	10.36	269.56	25.27
Price / Sales	N/A	1,288.04	596.64	100.41
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	11.53	17.39	13.00	6.30
Net Income	-$505.61M	-$13.32M	$3.45B	$347.83M
7 Day Performance	2.73%	0.34%	0.57%	0.94%
1 Month Performance	5.86%	0.13%	1.22%	0.90%
1 Year Performance	170.00%	53.78%	66.67%	20.40%

Immunovant Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMVT Immunovant	1.6597 of 5 stars	$41.31 -1.2%	$44.00 +6.5%	+163.2%	$8.53B	N/A	N/A	120	Positive News
BIIB Biogen	4.0463 of 5 stars	$201.82 -0.6%	$223.89 +10.9%	+55.8%	$29.99B	$9.89B	35.72	7,500	Analyst Downgrade
ALNY Alnylam Pharmaceuticals	4.8288 of 5 stars	$220.33 +7.2%	$402.67 +82.8%	-47.5%	$27.50B	$3.71B	40.95	2,770	Analyst Forecast
ROIV Roivant Sciences	1.7335 of 5 stars	$33.32 -1.7%	$33.59 +0.8%	+203.4%	$24.39B	$8.26M	N/A	860	Positive News Gap Down
INCY Incyte	3.6297 of 5 stars	$118.43 -0.9%	$119.60 +1.0%	+40.4%	$24.23B	$5.14B	15.09	2,844	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMVT) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunovant (IMVT) Competitors